SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Plandai Biotechnology Inc (OTCMKTS:PLPL) started with its declining spree in July and since then the stock has dropped from over $0.25 to current level of $0.130. In last trading session, the stock declined more than 7% to close the trading session at $0.130. The decline came at a share volume of 18,478 compared to average monthly share volume of 71,326.

Previously, the company announced that USN extended its association with the company. The sports and wellness group will use Phytofare as ingredient in many more products. Plandai obtained the first purchase order back in May. It was awarded from one of the contract manufacturers of USN based in the South African market.

As per the extended deal, the additional products with Phytofare as ingredient will be unveiled in New Zealand and Australia. The main ingredient in the product, Phytofare®, has ability to enhance ingredients in the blood.

Flex Pharma Inc (NASDAQ:FLKS) Engages Kathie Lindemann As COO

Flex Pharma Inc (NASDAQ:FLKS) reported that they engaged Kathie Lindemann as company’s Chief Operating Officer, reporting to the President and CEO, Christoph Westphal M.D., Ph.D. Prior to Flex Pharma, she served as COO at DAVIDs TEA Inc. Ms Lindemann was associated with Starbucks Corporation (NASDAQ:SBUX) for almost nineteen years where she served on various leadership roles including SVP, Starbucks Foodservice, SVP International Operations, SVP US Business Operations, and others.

In unrelated news, Flex Pharma reported that Mr. Robert J. Perez will join company’s Board. Perez is an ex-Chief Executive of Cubist Pharmaceuticals Inc (NASDAQ:CBST). He was SVP, Sales and Marketing and significantly contributed in Cubicin® launch.

Why Is Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) In Focus?

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) reported that it received an initial award notice of a Fast Track SBIR grant. Following the news, the stock has been moving up on the chart. The positive momentum continued in last trading session as stock gained more than 2% to close the day at $2.34.